CVE-2024-47531 Security Vulnerability & Exploit Details

CVE-2024-47531
Vulnerability Scoring

3.5

/10

Moderate Risk

Exploiting CVE-2024-47531 requires specific conditions, leading to a moderate security impact.

Attack Complexity Details

Attack Complexity: Low
Exploits can be performed without significant complexity or special conditions.
Attack Vector: Network
Vulnerability is exploitable over a network without physical access.
Privileges Required: Low
Some privileges are necessary to exploit the vulnerability.
Scope: Unchanged
Exploit remains within the originally vulnerable component.
User Interaction: Required
User interaction is necessary for successful exploitation.

CVE-2024-47531 Details

Status: Analyzed

Last updated: 🕕 15 Nov 2024, 18:02 UTC
Originally published on: 🕓 30 Sep 2024, 16:15 UTC

Time between publication and last update: 46 days

CVSS Release: version 3

CVSS3 Source

nvd@nist.gov

CVSS3 Type

Primary

CVSS3 Vector

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:N/I:L/A:N

CVE-2024-47531 Vulnerability Summary

CVE-2024-47531: Scout is a web-based visualizer for VCF-files. Due to the lack of sanitization in the filename, it is possible bypass intended file extension and make users download malicious files with any extension. With malicious content injected inside the file data and users unknowingly downloading it and opening may lead to the compromise of users' devices or data. This vulnerability is fixed in 4.89.

Assessing the Risk of CVE-2024-47531

Access Complexity Graph

The exploitability of CVE-2024-47531 depends on two key factors: attack complexity (the level of effort required to execute an exploit) and privileges required (the access level an attacker needs).

Exploitability Analysis for CVE-2024-47531

CVE-2024-47531 presents an accessible attack vector with minimal effort required. Restricting access controls and implementing security updates are critical to reducing exploitation risks.

Understanding AC and PR

A lower complexity and fewer privilege requirements make exploitation easier. Security teams should evaluate these aspects to determine the urgency of mitigation strategies, such as patch management and access control policies.

Attack Complexity (AC) measures the difficulty in executing an exploit. A high AC means that specific conditions must be met, making an attack more challenging, while a low AC means the vulnerability can be exploited with minimal effort.

Privileges Required (PR) determine the level of system access necessary for an attack. Vulnerabilities requiring no privileges are more accessible to attackers, whereas high privilege requirements limit exploitation to authorized users with elevated access.

CVSS Score Breakdown Chart

Above is the CVSS Sub-score Breakdown for CVE-2024-47531, illustrating how Base, Impact, and Exploitability factors combine to form the overall severity rating. A higher sub-score typically indicates a more severe or easier-to-exploit vulnerability.

CIA Impact Analysis

Below is the Impact Analysis for CVE-2024-47531, showing how Confidentiality, Integrity, and Availability might be affected if the vulnerability is exploited. Higher values usually signal greater potential damage.

Confidentiality: None
CVE-2024-47531 has no significant impact on data confidentiality.
Integrity: Low
Exploiting CVE-2024-47531 may cause minor changes to data without severely impacting its accuracy.
Availability: None
CVE-2024-47531 does not impact system availability.

Exploit Prediction Scoring System (EPSS)

The EPSS score estimates the probability that this vulnerability will be exploited in the near future.

EPSS Score: 0.045% (probability of exploit)

EPSS Percentile: 16.73% (lower percentile = lower relative risk)
This vulnerability is less risky than approximately 83.27% of others.

CVE-2024-47531 References

External References

CWE Common Weakness Enumeration

CWE-116

CAPEC Common Attack Pattern Enumeration and Classification

Cross Zone Scripting CAPEC-104 An attacker is able to cause a victim to load content into their web-browser that bypasses security zone controls and gain access to increased privileges to execute scripting code or other web objects such as unsigned ActiveX controls or applets. This is a privilege elevation attack targeted at zone-based web-browser security.
User-Controlled Filename CAPEC-73 An attack of this type involves an adversary inserting malicious characters (such as a XSS redirection) into a filename, directly or indirectly that is then used by the target software to generate HTML text or other potentially executable content. Many websites rely on user-generated content and dynamically build resources like files, filenames, and URL links directly from user supplied data. In this attack pattern, the attacker uploads code that can execute in the client browser and/or redirect the client browser to a site that the attacker owns. All XSS attack payload variants can be used to pass and exploit these vulnerabilities.
Web Server Logs Tampering CAPEC-81 Web Logs Tampering attacks involve an attacker injecting, deleting or otherwise tampering with the contents of web logs typically for the purposes of masking other malicious behavior. Additionally, writing malicious data to log files may target jobs, filters, reports, and other agents that process the logs in an asynchronous attack pattern. This pattern of attack is similar to "Log Injection-Tampering-Forging" except that in this case, the attack is targeting the logs of the web server and not the application.
AJAX Footprinting CAPEC-85 This attack utilizes the frequent client-server roundtrips in Ajax conversation to scan a system. While Ajax does not open up new vulnerabilities per se, it does optimize them from an attacker point of view. A common first step for an attacker is to footprint the target environment to understand what attacks will work. Since footprinting relies on enumeration, the conversational pattern of rapid, multiple requests and responses that are typical in Ajax applications enable an attacker to look for many vulnerabilities, well-known ports, network locations and so on. The knowledge gained through Ajax fingerprinting can be used to support other attacks, such as XSS.

Vulnerable Configurations

cpe:2.3:a:clinical-genomics:scout:-:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:-:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2.0:rc1:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2.0:rc1:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2.0:rc2:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2.0:rc2:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2.0:rc3:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:0.2.0:rc3:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.0.0:-:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.0.0:-:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.0.0:rc1:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.0.0:rc1:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.0.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.0.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.2.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.2.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.2.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.2.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.2.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.2.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.3.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.3.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.4.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.4.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.5.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:1.5.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:2.0.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:2.0.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:2.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:2.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.0.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.0.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.2.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.2.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.3.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.3.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.4.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.4.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.4.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.4.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.5.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.5.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.5.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.5.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.5.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:3.5.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.0.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.0.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.4:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.1.4:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.2.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.2.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.2.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.2.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.2.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.2.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.3.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.4.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.4.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.4.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.4.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.5.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.5.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.5.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.5.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.6.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.6.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.6.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.6.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.7.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.8.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.9.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.9.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.10.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.10.0:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.10.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.10.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.11:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.11:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.11.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.11.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.4:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.12.4:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.13:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.13:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.13.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.13.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.14:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.14:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.14.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.14.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.15:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.15:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.15.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.15.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.16:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.16:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.16.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.16.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.17:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.17:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.17.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.17.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.18:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.18:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.19:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.19:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.20:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.20:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.21:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.21:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.21.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.21.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.21.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.21.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.22:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.22:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.23:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.23:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.24:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.24:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.24.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.24.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.25:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.25:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.26:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.26:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.26.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.26.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.27:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.27:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.28:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.28:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.29:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.29:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.29.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.29.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.30:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.30:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.30.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.30.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.30.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.30.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.31:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.31:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.31.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.31.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.32:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.32:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.32.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.32.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.33:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.33:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.33.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.33.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.34:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.34:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.35:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.35:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.36:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.36:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.37:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.37:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.38:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.38:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.39:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.39:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.40:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.40:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.40.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.40.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.41:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.41:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.41.1:hotfix:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.41.1:hotfix:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.42:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.42:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.42.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.42.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.43:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.43:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.43.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.43.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.44:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.44:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.45:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.45:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.46:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.46:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.46.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.46.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.47:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.47:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.48:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.48:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.48.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.48.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.49:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.49:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.50:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.50:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.50.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.50.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.51:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.51:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.52:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.52:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.53:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.53:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.54:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.54:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.55:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.55:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.56:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.56:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.1:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.2:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.3:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.4:*:*:*:*:*:*:*
cpe:2.3:a:clinical-genomics:scout:4.57.4:*:*:*:*:*:*:*

Protect Your Infrastructure against CVE-2024-47531: Combat Critical CVE Threats

Stay updated with real-time CVE vulnerabilities and take action to secure your systems. Enhance your cybersecurity posture with the latest threat intelligence and mitigation techniques. Develop the skills necessary to defend against CVEs and secure critical infrastructures. Join the top cybersecurity professionals safeguarding today's infrastructures.

Other 5 Recently Published CVEs Vulnerabilities

CVE-2025-2122 – A vulnerability classified as problematic was found in Thinkware Car Dashcam F800 Pro up to 20250226. Affected by this vulnerability is an unknown ...
CVE-2025-27636 – Bypass/Injection vulnerability in Apache Camel. This issue affects Apache Camel: from 4.10.0 through <= 4.10.1, from 4.8.0 through <= 4.8.4, from ...
CVE-2025-2121 – A vulnerability classified as critical has been found in Thinkware Car Dashcam F800 Pro up to 20250226. Affected is an unknown function of the comp...
CVE-2025-2120 – A vulnerability was found in Thinkware Car Dashcam F800 Pro up to 20250226. It has been rated as problematic. This issue affects some unknown proce...
CVE-2025-2119 – A vulnerability was found in Thinkware Car Dashcam F800 Pro up to 20250226. It has been declared as problematic. This vulnerability affects unknown...

CVE-2024-47531 Vulnerability Scoring